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Background and Aim: Toll-like receptors (TLRs) modulate T cell responses in diverse diseases. Co-stimulation of T cell 
activation via TLR9 induces production of interferon gamma (IFN-γ), priming of which is critical for differentiation of pro-
inflammatory macrophages. These macrophages have a crucial role in nonalcoholic fatty liver disease (NAFLD). We aimed 
to evaluate the expression of TLR9 protein on T cells and the consequences of TLR9-mediated triggering of these cells in 
patients with NAFLD.
Methods: Our study included 34 patients with simple steatosis, 34 patients with nonalcoholic steatohepatitis, eight 
patients with NAFLD who met general diagnostic criteria but lacked histological diagnosis, and 51 control subjects. We 
used a synthetic TLR9 ligand to co-stimulate T cells. We measured TLR9 expression in liver and peripheral T cells and 
CD69 and IFN-γ as phenotypic markers of T cell activation and differentiation by flow cytometry.
Results: TLR9 expression on liver and peripheral T cells was lowest in patients with simple steatosis and was positively 
associated with anthropometric, biochemical, and histopathological features of NAFLD. In vitro co-stimulation of T cells 
from patients with simple steatosis induced a limited number of IFN-γ-producing CD8+ T cells. At baseline, these patients 
showed a low frequency of circulating type 1 CD8+ cells.
Conclusions: The positive associations between TLR9 and anthropometric, clinical, and histological features and the 
crucial role of IFN-γ-in NAFLD suggest that limited TLR9 expression and production of IFN-γ play a protective role in 
patients with simple steatosis. Clin Mol Hepatol 2019 Dec 5. [Epub ahead of print]
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INTRODUCTION 
Nonalcoholic fatty liver diseases (NAFLD) are a spectrum of liver 
diseases including simple steatosis (SS) and steatohepatitis as its 
more progressive form.1 The hallmark of nonalcoholic steatohepa-
titis (NASH) is the intrahepatic recruitment of inflammatory cells. 
All cells able to produce interferon gamma (IFN-γ) in inflammation 
can regulate the polarization of macrophages towards a pro-in-
flammatory phenotype. Compared with NASH, SS patients exhibit 
higher numbers of intrahepatic macrophages of anti-inflammatory 
nature.2
Toll-like receptors (TLR) are a family of pattern recognition re-
ceptors able to activate the innate immune system.3 TLR9-mediat-
ed triggering of hepatic Kupffer cells is critically involved in NASH 
development4 firstly because NAFLD-associated small intestinal 
bacterial overgrowth2,3 promotes the entry of TLR9 ligands of bac-
terial origin into the liver5 and secondly, due to the presence of 
microparticles of hepatocyte origin carrying mitochondrial DNA 
which also functions as TLR9 ligands.6
T cell responses in diseases of diverse etiology are modulated 
by TLRs expression,7-11 including TLR9.7,8 T cells co-stimulation via 
T cell receptor and TLR9 causes T cell activation and IFN-γ pro-
duction.12 We have previously identified the alteration of different 
T cell subsets in NASH patients13 and other authors confirmed a 
key role for T cells in NASH.14 A low intrahepatic expression of 
TLR9 mRNA was reported in SS.15 though it may probably come 
from the liver parenchyma than from T cells. So far, no study has 
evaluated TLR9 protein expression on T cells and the consequenc-
es of TLR9-mediated triggering in NAFLD. We hypothesized that T 
cells from patients with SS have a decreased expression of TLR9 
and a limited production of IFN-γ.
MATERIALS AND METHODS
Patients and general procedures
Patients with NAFLD come from different centers of Buenos Ai-
res whereas samples processing was entirely performed at the 
Clinical Hospital “José de San Martín”. NAFLD patients group 1 
comprised 68 individuals with biopsy-proven diagnosis of SS 
(n=34) or NASH (n=34). Its diagnosis was based on a daily alco-
hol consumption <20 g (females) or 30 g (males), absence of oth-
er causes of liver disease and abdominal ultrasound.16 The histo-
logical diagnosis was based on the NAFLD Activity Score17 and 
fibrosis staging18 with score values ≥5 as the cut-off for NASH. 
Liver biopsies and concomitant blood samples were used to evalu-
ate TLR9 protein expression. NAFLD patients from group 2 were 
eight individuals who met the general criteria for NAFLD diagnosis 
but lacked histological diagnosis, hereafter called “NAFLD pa-
tients”, used to evaluate TLR9 mRNA expression. Control group 1 
included 11 metabolically healthy individuals who underwent anti-
reflux surgery or cholecystectomy and did not have  fatty liver 
which was confirmed by biopsy. Their biopsy samples were used 
to evaluate TLR9 protein expression. Control group 2 included 40 
individuals recruited among the staff members of the Institute of 
Immunology, Genetics and Metabolism. All of the control individ-
uals were given information of the study and those who intended 
to participate gave their written informed consent. Patients in the 
control groups did not received any medications within 6 months 
before the study, had low daily alcohol consumption, a body mass 
index (BMI) <25 kg/m2 and a waist circumference <80 cm (fe-
males) or 94 cm (males). Their blood samples were used in differ-
ent experiments as indicated. The BMI and waist circumference 
were evaluated according to the World Health Organization crite-
ria.19 Homeostasis Assessment Model for insulin resistance was 
calculated as glucose (mg/dL) × insulin (µU/mL) / 405 and mea-
sures were performed using commercial kits. Plasma levels of to-
tal cholesterol and triglycerides, aspartate and alanine amino-
transferases were determined in a Cobas C-501 autoanalyzer 
(Roche Diagnostics, Mannheim, Germany). As transaminases nor-
mal levels slightly vary depending on the individual laboratory´s 
reference values, data were normalized before use. The experi-
mental protocols and sample studies were approved by the local 
Ethics Committee (Clinic Hospital Ethics Committee, “Immuno-
pathogenic factors that determine the progression of diseases as-
Study Highlights
We demonstrated a limited expression of Toll-like receptor 9 (TLR9) and interferon gamma (IFN-γ) production by T cells in patients with simple ste-
atosis (SS). The limited expression of TLR9 on T cells was directly associated with lower liver necroinflammatory activity and fibrosis, and lower antro-
phometric and biochemical alterations of nonalcoholic fatty liver disease. Besides, co-stimulation of T cell activation via TLR9 induced a limited num-
ber of IFN-γ-producing CD8+ T cells in SS patients. Accordingly, these patients showed a low frequency of circulating type 1 CD8+ cells whereas 
additional pro-inflammatory signals may be responsible for the higher frequency observed at baseline in the context of steatohepatitis.
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sociated with metabolic syndrome”, March 6, 2017) which uses 
the internationally endorsed standards for the application of the 
Helsinki Declaration.
Reagents
We used Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden), 
TRIZOL® reagent and Roswell Park Memorial Institute 1640 me-
dium (Life Technologies, Gaithersburg, MD, USA) and gentamicin, 
glutamine, ionomycin, fetal bovine serum, phorbol 12-myristate 
13-acetate and brefeldin A (Sigma Chemical Co, Saint Louis, MO, 
USA). Phorbol 12-myristate 13-acetate was prepared in dimethyl 
sulfoxide at 25 µg/mL. We used BD™ IMag anti-human CD3 
magnetic particles, PermWash™, Cytofix/Cytoperm, anti-human 
CD3 monoclonal antibody (UCHT1) for cell stimulation, anti-TLR9-
phycoerythrin (PE) (eB72-1665) and anti-CD4-Peridinin-Chloro-
phyll-protein (PerCP) (SK3) from Becton-Dickinson (San Diego, 
CA, USA), anti-CD8-Fluorescein isothiocyanate (FITC) (UCHT-4), 
anti-CD69-PE (FN50) and anti-IFN-γ-PE (B27) from ImmunoTools 
GmbH (Friesoythe, Germany). The synthetic cytidine-phosphate-
guanosine oligodeoxynucleotide (CpG-ODN) 2395 5’-tcgtcgttttcg-
gcgcgcgccg-3’ (Thermo Fisher Scientific, Waltham, MA, USA) 
used as TLR9 agonist was solubilized in sterile endotoxin-free wa-
ter at 100 µM and stored at 20X until use.
Cell isolation 
Peripheral blood mononuclear cells were obtained using Ficoll-
Hypaque gradients and resuspended in Roswell Park Memorial In-
stitute 1640 medium 10% fetal bovine serum, 2 mmol/L L-gluta-
mine, and 50 µg/mL gentamicin. Twice-enriched fractions of CD3+ 
T cells were isolated from peripheral blood mononuclear cells 
(PBMC) by negative selection using magnetic particles. Recovered 
cells were at least 98% CD3+. We handled liver tissues at 4ºC us-
ing a hands-on homogenization method, washed liver cell sus-
pensions twice in phosphate buffered saline and harvested cells 
by centrifugation.
Quantitative polymerase chain reaction
Total RNA was isolated from CD3+ cells using TRIZOL® reagent 
and reverse transcribed using oligo (dT) primers and Super-
Script™ II First-Strand Synthesis System (Invitrogen, Life Technolo-
gies, Carlsbad, CA, USA). Forward and reverse primers: TLR9, 
5´-GAAGGGACCTCGAGTGTGAAG-3´ and 5´-GTAGGAAGGCAG-
GCAAGGTA-3´; glyceraldehyde 3-phosphate dehydrogenase, 
5´-CGACCACTTTGTCA AGCTCA-3´ and 5´-ACATGGCCTC-
CAAGGAGTAA-3´. Quantitative polymerase chain reaction was 
performed on a Stratagene Mx3005p RT-PCR Detection System 
(Agilent Technologies, La Jolla, CA, USA) using SYBR® Green PCR 
Master Mix (applied Biosystems, Life Technologies). Relative gene 
expression and fold change expression were calculated using the 
comparative Ct method.20
Intracytoplasmic TLR9 protein measurement
Suspension of 5×105 isolated peripheral blood mononuclear 
cells or liver cells was centrifuged at 2,000 rpm for 5 minutes and 
incubated with anti-CD4- PerCP and anti-CD8-FITC in darkness at 
4ºC for 20 minutes. Fixed and permeabilized cells were incubated 
with anti-TLR9-PE or the isotype control in darkness at 4ºC for 40 
minutes, washed twice in PermWashTM 1X, resuspended in phos-
phate buffered saline 1X and assessed using flow cytometry. At 
least 100,000 events were acquired on a FACSCalibur flow cy-
tometer (BD). The acquired data were analyzed using FlowJo soft-
ware version 5.7.2 (Treestar, San Carlos, CA, USA). To analyze 
TLR9 expression, lymphocytes were gated on a forward and side-
scatter plot and further gated based on CD4 or CD8 expression. 
TLR9 expression was expressed as a percent difference compared 
with isotype control using mean fluorescence intensity (MFI) val-
ues as follows: [(MFI of TLR9 / MFI of isotype control) - 1 / MFI of 
isotype control × 100].9
CD69 measurement 
1×106 isolated CD3+ cells were activated with soluble anti-CD3 
(250 ng/mL) alone or in combination with 2 µM CpG-ODN in 24-
well culture plates at 37ºC for 24 hours. The cells were harvested 
by centrifugation, incubated with anti-CD4-PerCP, anti-CD8-FITC 
and anti-CD69-PE monoclonal antibodies in darkness at 4ºC, 
washed twice and resuspended in phosphate buffered saline 1X. 
A frequency index for CD69+ cells was calculated within CD4+ and 
CD8+ cell compartments as the ratio of frequencies observed after 
treatments with anti-CD3+CpG-ODN and anti-CD3 alone.
Intracytoplasmic IFN-γ staining
To evaluate the frequency of IFN-γ+ cells at baseline, peripheral 
blood mononuclear cells were stimulated with 25 ng/mL phorbol 
12-myristate 13-acetate and 1 mM Ionomycin in the presence of 
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1 mM Brefeldin A at 37°C for 4 hours. After stimulation, cell sur-
face staining using anti-CD4-PerCP and anti-CD8-FITC monoclo-
nal antibodies was performed as described above, and intracyto-
plasmic detection of IFN-γ was done as described for TLR9. 
Lymphocytes were gated on a forward versus size scatter plot, the 
lymphoid region was further gated based on CD4 or CD8 expres-
sion, and IFN-γ expression was measured in the selected popula-
tions. To evaluate the frequency of IFN-γ+ cells after co-stimula-
tion, isolated PBMC were divided into 5×105 cells per well each 
containing 500 µL of Roswell Park Memorial Institute medium 
and stimulated at 37ºC for 18 hours in the presence of 1 mM 
Brefeldin A with 250 ng/mL soluble anti-CD3 alone or anti-CD3+2 
uM CpG-ODN in 24-well culture plates. A frequency index for 
IFN-γ+ cells was calculated as described for CD69.
Statistical analysis.
We used GraphPad Prism software (GraphPad, San Diego, CA, 
USA). We performed the two-tailed Mann-Whitney U test (two 
groups), the Kruskal-Wallis with Dunn’s multiple comparison test 
(three or more groups), and Wilcoxon paired test (intragroup com-
parisons). Data were summarized using the median, first and third 
interquartiles and minimum and maximum values. We used the 
Spearman’s rank correlation analysis to measure the statistical re-
lations between TLR9 expression and continuous variables. 
P<0.05 was accepted as a significant value.
RESULTS
Characteristics of patients with NAFLD and control 
subjects
Anthropometric measurements, blood analysis and ultrasonog-
raphy examination were performed at the beginning of the study 
(Table 1). All patients showed overweight or obesity and altered 
values of waist circumference and homeostasis assessment model 
for insulin resistance. We observed higher levels of aspartate and 
alanine aminotransferases in NASH than in SS patients from group 
1. Anthropometric and biochemical values from control subjects 
fell into the reference ranges indicated (not shown). We described 
a direct relationship between plasma triglycerides concentration 
and fat content in NAFLD patients after comparing triglyceride 
levels between patients with steatosis scores “≤1” and “≥2” 
Table 1. Demographic and baseline data of the study cohort
Variable
Group 1 Group 2
SS (n=34) NASH (n=34) SS vs. NASH NAFLD (n=8)
Gender, M/F 17/17 15/19 5/3
Age (years) 44 (33–59) 55 (41–58) NS 39 (25–51)
BMI (kg/m2) 33.25 (26.50–39.38) 31.00 (28.80–40.00) NS 31.23 (28.96–42.60)
Waist circumference (cm) 110.00 (99.00–116.30) 98.00 (94.00–105.00) NS* 105.00 (96.00–120.00)
HOMA-IR 4.50 (2.30–8.20) 4.95 (3.10–7.85) NS 5.80 (2.40–8.10)
Fasting blood glucose (mg/dL) 102.00 (96.50–116.80) 127.00 (98.00–137.00) NS 97.00 (88.00–108.00)
Insulin (µU/mL) 16.00 (10.60–30.50) 21.00 (9.12–26.50) NS 20.80 (10.60–30.50)
Total cholesterol (mg/dL) 190.00 (168.00–233.00) 208.00 (192.00–247.00) NS 185.00 (163.00–224.00)
Total triglycerides (mg/dL) 153.00 (88.50–218.50) 165.00 (98.00–189.00) NS 153.00 (90.00–196.00)
AST (UI/L) 36.00 (27.50–43.50) 96.50 (73.50–121.25) 0.0003 75.00 (28.00–121.00)
ALT (UI/L) 47.50 (32.75–58.25) 137.00 (71.50–199.50) 0.0028 77.50 (41.25–165.80)
The table shows demographic and baseline data of NAFLD patients with biopsy-proven diagnosis of SS and NASH patients from group 1, and patients which 
met the general criteria for NAFLD but lacked the histological diagnosis from group 2. Results are summarized as median values (first-third quartiles). The 
Mann-Whitney U test was used to compare continuous variables between SS and NASH patients. Reference values: BMI: 25.00-29.90 kg/m2 (overweight), 
greater than 30.00 kg/m2 (obesity). Waist circumference: <84 cm (F) or 94 cm (M). HOMA-IR <2.5. Insulin: 2-20 µU/mL. Fasting blood glucose: <100 mg/dL. 
Total cholesterol: 150 to 199 mg/d. Total triglycerides: <150 mg/dL. Aspartate transaminases: <48 UI/L. Alanine transaminases: <32 UI/L.
SS, simple steatosis; NASH, nonalcoholic steatohepatitis; NAFLD, nonalcoholic fatty liver diseases; M, male; F, female; BMI, body mass index; NS, no significant 
differences; HOMA-IR, homeostatic assessment model for insulin resistance; AST, aspartate transaminases; ALT, alanine transaminases.
*Comparisons were performed separately, between males or females with SS and NASH.
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(P=0.0342, not shown). 
Relationship between TLR9 expression, histological 
and clinic-pathological features of NAFLD
We assessed TLR9 protein expression in liver cell suspensions 
(Fig. 1A, B). TLR9 expression was lowest within the CD4+ cell 
compartment in SS patients (P<0.05, vs. controls and vs. NASH 
patients) (Fig. 1B). TLR9 expression on CD8+ T cells was similar 
among groups. To get further insight into the biological relevance 
of these findings, we evaluated the relationship between TLR9 
expression and NAFLD histological features (Table 2) after 
Figure 1. Intrahepatic and peripheral TLR9 protein expression. Lymphocytes were gated on a forward and side-scatter plot, and the lymphoid region 
was further gated based on CD4 or CD8 expression (not shown). (A, B) Intrahepatic TLR9 expression. (A) Representative flow cytometric histograms 
showing TLR9 expression within a CD4+ cell compartment in a control subject, a patient with simple steatosis (SS), and a patient with nonalcoholic ste-
atohepatitis (NASH). The ordinates and abscissas represent counts and fluorescence intensity, respectively. (B) The bar graph shows TLR9 expression in 
control subjects (n=11, group 1), patients with SS (n=13, group 1), and patients with NASH (n=14, group 1). TLR9 expression was expressed as a percent-
age difference in mean fluorescence intensity (MFI) value compared with the isotype control as follows: [(MFI of TLR9 / MFI of isotype control-1 / MFI of 
isotype control × 100]. We used the Kruscal-Wallis with Dunń s multiple comparison test to compare data among the three groups. (C, D) Peripheral 
TLR9 expression. (C) Representative flow cytometric histograms showing TLR9 expression within intrahepatic CD4+ and CD8+ cell compartments in a 
control subject, a patient with SS, and a patient with NASH. (D) The bar graph shows TLR9 expression in control subjects and patients mentioned in (B). 
TLR9 expression was calculated as above. We used the Kruscal-Wallis with Dunń s multiple comparison test to compare data among the three groups. 
In (B) and (D), the lines in each box represent the median values, and the horizontal boundaries of the boxes represent the first and third quartiles. The 
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stratification of NAFLD patients according to their histological 
scores within the categories indicated in Table 2. Our results 
showed a positive association between TLR9 expression in CD4+ 
cells and liver damage. Then, we assessed TLR9 protein expres-
sion in peripheral blood mononuclear cells from the individuals 
previously evaluated (Fig. 1C, D). SS patients showed the lowest 
TLR9 expression within CD4+ (P=0.0219) and CD8+ (P=0.0022) 
cell compartments (Fig. 1D). A quantitative polymerase chain re-
action-based analysis of TLR9 mRNA in CD3+ T cells confirmed a 
decreased expression of TLR9 mRNA in about 50% of patients 
(not shown). To assess the relationship between TLR9 expression 
at peripheral blood and clinic-pathological variables relevant to 
NAFLD, we performed a correlation analysis (Table 3). NAFLD pa-
tients with a lower alteration of BMI and aminotransferases activ-
ity exhibited a lower TLR9 expression within both cell compart-
ments. We also found a positive association between plasma 
triglycerides concentration and TLR9 expression in peripheral 
CD8+ cells. 
Table 2. Relationships between TLR9 expression and necroinflammatory activity and fibrosis in NAFLD and comparison of TLR9 protein expression on 
intrahepatic T cells
Cell type Score ≤1 Score ≥2 P-value
A.  Comparison between patients grouped according to 
their histological scores of steatosis degree*
14 13
CD4+ 49.87 (44.10–57.36) 165.30 (163.3–229.4) 0.0042
CD8+ 179.30 (137.90–284.00) 192.9 (149.5–236.6) NS
B.  Comparison between patients grouped according to 
their histological scores of ballooning degeneration*
14 13
CD4+ 53.6 (41.2–138.2) 165.4 (162.6–248.1) 0.0208
CD8+ 159.5 (138.3–336.3) 207.1 (178.8–226.8) NS
C.  Comparison between patients grouped according to 
their histological scores of lobular inflammation*
19 8
CD4+ 53.3 (38.3–111.3) 165.4 (164.0–248.1) 0.0227
CD8+ 179.3 (139.7–284.0) 207.1 (178.8–226.8) NS
D.  Comparison between patients grouped according to 
their fibrosis stage*
16 11
CD4+ 53.6 (41.2–138.2) 165.4 (162.6–248.1) 0.0381
CD8+ 159.5 (138.3–336.3) 207.1 (178.8–246.4) NS
The table shows the relationship between TLR9 expression on intrahepatic T cells and necroinflammatory activity (A-C) or fibrosis (D). NAFLD patients 
included in Fig. 1 (n=27) were classified within two categories (as indicated in A-D), according to their histological scores of steatosis degree (A), ballooning 
degeneration (B), lobular inflammation (C), and fibrosis stage (D). Intrahepatic TLR9 protein expression was calculated as a percent difference compared 
with isotype control using MFI values as follows: [(MFI of TLR9 / MFI of isotype control-1 / MFI of isotype control × 100]. We used the Mann-Whitney test to 
compare TLR9 expression between two categories, ns: no significant differences, P<0.05 was considered statistically significant.
NS, no significant differences; NAFLD, nonalcoholic fatty liver diseases; MFI, mean fluorescence intensity.
*Mean fluorescence intensity median values (first quartil-third quartil) are included in the table.
Table 3. TLR9 expression on circulating CD4+ and CD8+ cells and its re-
lationship with biochemical and clinicopathological variables of NAFLD
CD4+ CD8+
BMI* 0.6636 (0.0260) 0.8833 (0.0016)
Waist circumpherence* NS NS
Fasting blood glucose* NS NS
Total cholesterol* NS NS
Total triglycerides* NS 0.9500 (<0.0001)
AST* 0.7000 (0.0037) 0.6747 (0.0081)
ALT* 0.6929 (0.0042) 0.7011 (0.0052)
We used the Spearman´s rank correlation coefficients (r) to test the 
correlation between TLR9 expression and the anthropometric variables 
(BMI and waist circumpherence) or the plasma levels of selected metabolic 
variables, within peripheral CD4+ and CD8+ cell compartments. AST and ALT 
data were normalized according to the individual laboratory’s reference 
values.
BMI, body mass index; NS, no significant differences; AST, aspartate 
aminotransferases; ALT, alanine aminotransferases.
*Results summarized as r (P-value).
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Synergistic interaction between signals coming from 
T cell receptor and TLR9 in circulating T cells 
Given that a dysfunctionality of Kupffer cells in NASH21 might 
enhance the influx of TLR9 ligands into the systemic circulation 
and interact with T cells, we explored the consequences of TLR9-
mediated signaling of circulating T cells. Because cell activation is 
a prerequisite for T cell differentiation, we assessed CD69 upregu-
lation and IFN-γ production as phenotypic markers of these pro-
cesses. We employed isolated CD3+ cells for the assessment of 
cell activation to avoid the indirect effects of non-T cells,22 and 
the higher affinity of non-T cells for TLR9 ligands23 (Fig. 2). Re-
garding CD69 expression, the simultaneous addition of anti-CD3 
and CpG-ODN only provided co-stimulation to CD8+ cells (intra-
group comparisons: anti-CD3+CpG-ODN vs. anti-CD3 alone, not 
shown). Upregulation of CD69 was lowest in SS patients (P<0.01 
vs. controls, P<0.05 vs. NASH patients). The addition of CpG-
ODN did not affect CD69 expression (intragroup comparison: 
CpG-ODN treatment vs. medium, not shown). We employed pe-
ripheral blood mononuclear cells for cell differentiation assess-
ment as a representative cellular platform that would allow the 
association of these results with the frequencies of IFN-γ+-
producing cells at baseline (Fig. 3). Again, anti-CD3+CpG-ODN 
only provided co-stimulation for IFN-γ production to CD8+ cells 
(intragroup comparisons: anti-CD3+CpG-ODN vs. anti-CD3 alone, 
not shown). Up-regulation of IFN-γ+ cells was lowest in SS pa-
tients (P<0.05 vs. controls, P<0.01 vs. NASH patients). As for 
CD69, the addition of CpG-ODN did not alter intracellular IFN-γ 
production. Thus, our results demonstrated that T cells co-stimu-
lation promoted the lowest activation and differentiation of circu-
lating CD8+ cells in SS patients. The small size of our liver biopsies 
precluded its use for functional studies.
Frequency of IFN-γ+ cells at baseline
We measured the frequency of circulating IFN-γ+ T cells (Fig. 4). 
Figure 2. Synergistic interaction between T cell receptor and TLR9-me-
diated signaling in circulating cells. Isolated CD3+ cells from control sub-
jects (n=6, group 2), patients with simple steatosis (SS) (n=6, group 1), 
and patients with nonalcoholic steatohepatitis (NASH) (n=6, group 1) 
were cultured in Roswell Park Memorial Institute 1640 medium, stimulat-
ed with anti-CD3 alone or with anti-CD3+CpG-ODN. After 24 hours of 
culture, surface staining of CD4, CD8, and CD69 antigens was per-
formed. (A) Representative dot plots showing cells gated in the CD8+ re-
gion in a control subject, a patient with SS, and a patient with NASH. Dot 
plots show the percentage of CD69+ cells observed after treatment. 
(B) The frequency index for CD69+ cells within CD4+ and CD8+ cell com-
partments was calculated as a ratio of frequencies observed after treat-
ment with anti-CD3+CpG-ODN or anti-CD3 alone. The line in each box 
represents the median, the horizontal boundaries of the boxes repre-
sent the first and third quartiles, and the vertical error bars show the 
minimum and maximum values. We used the Kruscal-Wallis with Dunń s 
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Figure 3. Synergistic interaction between TLR9 and T cell receptor-me-
diated signaling for differentiation of CD8+ cells. Peripheral blood mono-
nuclear cells from control subjects were cultured in Roswell Park Memo-
rial Institute 1640 medium and stimulated with soluble anti-CD3 alone 
or with anti-CD3+CpG-ODN for 18 hours in the presence of Brefeldin A. 
After treatment, surface (CD4 or CD8) and intracellular (IFN-γ) staining 
was performed. Lymphocytes gated on a forward side and side scatter 
plot were further gated based on CD4 or CD8 expression (not shown). 
(A) Representative dot plots showing the frequency of IFN-γ+ lymphoid 
cells observed within the CD8+ gate after treatment of PBMC from a 
control subject, a simple steatosis (SS) patient, and a nonalcoholic ste-
atohepatitis (NASH) patient with anti-CD3 and anti-CD3+CpG-ODN. (B) 
Experiments performed with control subjects (n=5, group 2), patients 
with SS (n=5, group 1), and patients with NASH (n=5, group 1). The fre-
quency index for IFN-γ+ lymphoid cells was calculated for each cell com-
partment as a ratio of frequencies observed after treatment with anti-
CD3+CpG-ODN or anti-CD3 alone. The line in each box represents the 
median, the horizontal boundaries of the boxes represent the first and 
third quartiles, and the vertical error bars show the minimum and maxi-
mum values. We used the Kruscal-Wallis with Dunn’s multiple compari-
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Figure 4. Frequency of IFN-γ+ circulating cells in control subjects and pa-
tients with NAFLD. Peripheral blood mononuclear cells from control individ-
uals (n=11, group 2), patients with simple steatosis (SS) (n=8, group #1), and 
patients with nonalcoholic steatohepatitis (NASH) (n=9, group 1) were stim-
ulated for 4 hours with the protein kinase C stimulant phorbol 12-myristate 
13-acetate and ionomycin in the presence of Brefeldin A before surface (CD4 
or CD8) and intracellular (IFN-γ) staining. To analyze the frequency of IFN-γ+ 
cells, lymphocytes gated on a forward side and side scatter plot were fur-
ther gated based on CD4 or CD8 expression (not shown). The bar graph 
shows the percentage of IFN-γ-producing CD4+ and CD8+ cells. The line in 
each box represents the median, and the horizontal boundaries of the box-
es represent the first and third quartiles. The vertical error bars show the 
minimum and maximum values, *P<0.01; †P=0.0005. We used the Kruscal-
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The frequency of IFN-γ+ cells within CD4+ (P<0.01) and CD8+ 
(P=0.0005) cell compartments was higher in NASH patients than 
control subjects. SS patients and control subjects showed similar 
frequencies of type 1 CD8+ cells and T helper 1 cells, respectively. 
DISCUSSION 
We found positive associations between TLR9 expression on in-
trahepatic CD4+ T cells, necroinflammation and liver fibrosis, and 
between TLR9 expression on peripheral CD4+ and CD8+ T cells 
and clinic-pathological alterations of NAFLD such as BMI, plasma 
triglycerides concentration and aminotransferases activity. 
Relevant alterations of NAFLD in this study reflect liver disease or 
damage or predict the steatosis degree.24,25
The regulation of the inflammatory response in peripheral blood 
mononuclear cells is dependent on the metabolic status.26 Since 
metabolic alterations associated with NAFLD are similar among 
our patients, the decreased expression of TLR9 on T cells from SS 
patients may be independent from the metabolic context, particu-
larly from insulin even though it down modulates the expression 
of TLRs on T cells.27
We showed an overall downregulation of TLR9 on T cells from 
SS patients affecting intrahepatic CD4+ T cells as well as peripher-
al CD4+ and CD8+ T cells. It can be interpreted that this feature 
was likely a protection adaptation from hepatocellular injury 
whereas the observed unvarying expression in patients with 
NASH may be a failure of this regulatory mechanism. The cyto-
plasmic tails of all TLRs contain a Toll-interleukin 1 receptor (TIR) 
domain. The TIR domain of TLR9 provides a binding site for an 
ubiquitin-protein ligase regulating its abundance and activity.28 
Since ubiquitination of proteins mediates liver protection of pa-
tients with NAFLD,29 an increased ubiquitination of TLR9 might be 
involved in TLR9 downregulation on T cells from SS patients.
Our study confirms previous data concerning a synergism be-
tween T cell receptors and TLR9 during the induction of IFN-γ.12 
Furthermore, it reveals a milder response in CD8+ cells from SS 
patients following its co-stimulation. Precise mechanistic insight 
exists to priming effects of IFN-γ on macrophage activation to-
wards an inflammatory phenotype.30 We can speculate that if the 
consequences of the co-stimulation were similar for intrahepatic 
and peripheral T cells, the decreased intrahepatic TLR9 expression 
observed in SS patients would promote a low number of type 1 
CD8+ cells, favor the differentiation of anti-inflammatory Kupffer 
cells and protect against liver injury. In NASH, a failure of this reg-
ulatory mechanism would allow the progression of liver injury.
As compared with controls, NASH patients showed similar TLR9 
expression and similar responses after TLR9 ligation of T cells. 
However, NASH patients showed a higher frequency of IFN-γ-
producing cells than SS patients and controls at baseline. In the 
context of NASH, the presence of strong pro-inflammatory adipo-
kines and cytokines promoting type 1 CD8+ cells differentiation31 
supports these findings. The enrollment of patients in several cen-
ters from the specific area of Buenos Aires enhanced the possibili-
ty of generalizing our results to similar patients in similar settings. 
However, a limitation of our study was that a biopsy-proven diag-
nostic of NAFLD was unavailable from one of the participating 
centers. As we did not have an appropriate pilot study to estimate 
the sample size, we used information from previous studies in the 
same population, which allowed us to identify differences be-
tween groups provided that those differences genuinely existed in 
the population.13,32
A decreased expression of TLR9 and a limited production of 
IFN-γ by T cells from SS patients could play a protective role. T 
cells from NASH patients lack this mechanism and, furthermore, 
maybe influenced by strong pro-inflammatory signals of the mi-
croenvironment supporting the observed overproduction of IFN-γ. 
The impact of TLR9-mediated triggering of T cells within regulato-
ry circuits potentially involved in NAFLD deserves further investi-
gation. 
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